Immucell (ICCC) risk factors, FY2025 10-K

Immucell's FY2025 10-K, filed Mar 30, 2026, lists 36 risk factors in 5 groups. Against the prior year's 42: 6 new, 12 dropped, 19 substantially reworded.

Open ICCC in Gloom →
Immucell's chart, financials and news, free in your browser.Open ICCC in Gloom →
Risk factors listed
365 groups
New this year
6vs 42 last year
Dropped
12since the prior 10-K
Substantially reworded
19of those kept
Section length
6k wordsItem 1A

What the changes say

  • Re-Tain® strategy shifted from internal manufacture toward licensing, sale, or partnership after abandoning planned production.
  • First Defense® remains essential: 2025 operating income depended largely on its gross margin and product development discipline.
  • Capacity investment rose to $11.0 million, while planned expansion now depends on yield improvements and redeployed Re-Tain® assets.
  • Debt increased to $9.1 million, requiring approximately $2.0 million and $1.5 million of principal and interest payments in 2026 and 2027.

What changed since the prior 10-K

New

  • NewFinancial Risks

    Product sales

    Expanding First Defense® sales faces intense competition, higher pricing, uncertain demand, and regulatory approval barriers in international markets.

  • NewFinancial Risks

    Business interruption and business continuity

    A single operating location and inadequate interruption insurance could leave the company exposed to major losses if its facility becomes unavailable.

  • NewProduct Risks

    Colostrum collection

    Colostrum supply could decline because farms retain it, disease disrupts mostly single-state suppliers, competitors pay more, or quality is unsuitable.

  • NewRegulatory Risks

    Dairy Staffing

    Immigration enforcement could make it harder for colostrum suppliers and customers to recruit and retain workers needed for farm operations.

  • NewRegulatory Risks

    Industry

    Fewer cattle, lower calf values, disease, trade changes, protein-market shifts, or higher feed costs could shrink demand for First Defense®.

  • NewRegulatory Risks

    Ability to hire

    Growth depends on attracting specialized employees, obtaining USDA, FDA, and foreign approvals, and maintaining licensed manufacturing resources.

Dropped

  • Dropped

    OUTLINE TO ITEM 1A – RISK FACTORS

    Provided an outline heading for the Item 1A risk factors section.

  • DroppedFinancial Risks

    Risks associated with our funding strategy for Re-Tain®

  • DroppedProduct Risks

    1) A rejection of a tank of milk by a positive milk inhibitor test because too much of the milk in a bulk tank is comprised of milk from cows being treated with Re-Tain®, when tested randomly for inhibitors by a milk hauler, which could create legal liability

  • DroppedProduct Risks

    6) Producers either do not choose to use it or might use it improperly, rather than follow our label instructions to administer one dose after each of three consecutive milkings, or they may limit use within the herd in an abundance of caution to avoid the negative outcomes described above

  • DroppedRegulatory Risks

    Regulatory requirements for Re-Tain®

  • DroppedRegulatory Risks

    Immigration

  • DroppedRegulatory Risks

    Cattle count

  • DroppedRegulatory Risks

    Herd size

    Re-Tain® commercialization could lack sufficient cash and liquidity, with FDA approval remaining critical.

  • DroppedRegulatory Risks

    Milk cow price

  • DroppedRegulatory Risks

    Milk price

  • DroppedRegulatory Risks

    Feed Costs

  • DroppedRegulatory Risks

    Reliance on outside party to provide certain services under contract for us

Reworded

  • 100% rewrittenProduct Risks

    Risks pertaining to Re-Tain ®

    The risk now reflects the late-2025 decision to stop pursuing Re-Tain® manufacture and seek licensing, sale, or partnership, with no assurance of third-party interest.

    Was: Sales risks pertaining to Re-Tain®

  • 96% rewrittenFinancial Risks

    Gross margin on product sales

    Gross-margin risk now reports recovery from 30% to 41% in 2025, removes the 40% goal and Re-Tain® emphasis, and adds pricing, colostrum, contamination, and equipment risks.

  • 92% rewrittenFinancial Risks

    Net income (loss)

    The company now reports $1.6 million of 2025 operating income versus a $1.6 million loss in 2024, while removing specific First Defense® sales and Re-Tain® approval timing risks.

    Was: Projection of net (loss) income

  • 89% rewrittenFinancial Risks

    Inflation, supply disruptions, tax rates and economic downturns

    The discussion shifts from pandemic milk-price volatility to five-year inflation, higher customer input costs, improved calf prices, and recession effects on supply and demand.

  • 83% rewrittenFinancial Risks

    Exposure to interest rates and debt service obligations

    Debt details increased to $9.1 million at a 4.31% blended fixed rate, with approximately $2.0 million and $1.5 million of payments due in 2026 and 2027.

  • 77% rewrittenProduct Risks

    Reliance on sales of the First Defense ® product line

    The risk now states directly that the company would not be profitable without First Defense® gross margin and cites 2025 operating income.

  • 73% rewrittenFinancial Risks

    Currency exchange fluctuation

    Currency risk is narrowed to potential non-U.S. First Defense® expansion and customer pricing, removing discussion of more expensive international purchases.

  • 71% rewrittenProduct Risks

    Production capacity constraints

    Capacity is now measured at 4.6 million units in 2025 after $11.0 million invested, with expansion relying on yield improvements, redeployed Re-Tain® assets, contamination controls, and colostrum access.

  • 68% rewrittenGlobal Risks

    International Conflicts

  • 67% rewrittenGlobal Risks

    Bovine diseases

  • 65% rewrittenGlobal Risks

    Possible dilution

  • 61% rewrittenFinancial Risks

    Debt covenants

  • 59% rewrittenOther Risks

    Access to raw materials and contract manufacturing services

  • 59% rewrittenProduct Risks

    Concentration of sales

  • 57% rewrittenFinancial Risks

    Uncertainty of market size and product sales estimates

  • 42% rewrittenRegulatory Risks

    Competition from others

  • 30% rewrittenGlobal Risks

    Stock market valuation and liquidity

  • 24% rewrittenProduct Risks

    Product risks generally

  • 22% rewrittenRegulatory Risks

    Volatility of the dairy market

All 36 risk factors

Headings as the filing states them, in filing order.

Financial Risks

  1. 01Gross margin on product sales96% rewritten
  2. 02Product salesNew
  3. 03Net income (loss)92% rewritten
  4. 04Exposure to interest rates and debt service obligations83% rewritten
  5. 05Debt covenants61% rewritten
  6. 06Currency exchange fluctuation73% rewritten
  7. 07Inflation, supply disruptions, tax rates and economic downturns89% rewritten
  8. 08Business interruption and business continuityNew
  9. 09Uncertainty of market size and product sales estimates57% rewritten
  10. 10Net deferred tax assets

Product Risks

  1. 11Product risks generally24% rewritten
  2. 12Reliance on sales of the First Defense ® product line77% rewritten
  3. 13Concentration of sales59% rewritten
  4. 14Production capacity constraints71% rewritten
  5. 15Contamination events, equipment failures and gross margin from our production process
  6. 16Colostrum collectionNew
  7. 17Product liability
  8. 18Risks pertaining to Re-Tain ®100% rewritten

Regulatory Risks

  1. 19Regulatory requirements for the First Defense ® product line
  2. 20Regulatory requirements limiting access to suppliers and customer base
  3. 21Dairy StaffingNew
  4. 22IndustryNew
  5. 23Volatility of the dairy market22% rewritten
  6. 24Dependence on key personnel
  7. 25Competition from others42% rewritten
  8. 26Ability to hireNew

Global Risks

  1. 27Tariffs and Trade Policies
  2. 28International Conflicts68% rewritten
  3. 29Climate change
  4. 30Bovine diseases67% rewritten
  5. 31Stock market valuation and liquidity30% rewritten
  6. 32No expectation to pay any dividends or repurchase stock for the foreseeable future
  7. 33Possible dilution65% rewritten

Other Risks

  1. 34Access to raw materials and contract manufacturing services59% rewritten
  2. 35Failure to protect intellectual property
  3. 36Increasing dependence on the continuous and reliable operation of our information technology systems

Other Immucell 10-Ks

  • FY2024 10-K risk factors
    42 risks

    Re-Tain® commercialization depends on FDA approval, funding, customer adoption, and reliable contract manufacturing.

    Filed Mar 28, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.